Athera Biotechnologies AB:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Athera Biotechnologies AB - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C3045
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:18
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Athera Biotechnologies AB (Athera) is a clinical stage biopharmaceutical company that focuses on the development of anti-inflammatory biological candidate drugs for the prevention and treatment of immunovascular disease. The company develops a proprietary clinical development stage program, PC-mAb, a human monoclonal antibody used to treat vascular disease, peripheral artery disease, heart failure, arteriovenous dysfunction in dialysis patients, and arterial inflammation. It also develops a proprietary companion diagnostic CVDefine kit to identify patients with low levels of natural anti-PC antibodies. Athera offers clinical development and clinical trials services. The company partners with pharmaceutical, biotechnology and diagnostics companies. Athera is headquartered in Stockholm, Sweden.

Athera Biotechnologies AB – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Athera Biotechnologies AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Athera Biotechnologies AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Athera Biotechnologies AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Athera Biotechnologies AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Athera Biotechnologies AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Athera Biotechnologies AB, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Athera Biotech Raises USD7.2 Million in Venture Financing 10
Athera Biotechnologies Raises USD2.8 Million in Venture Financing 11
Partnerships 12
Athera Biotech Enters Into Agreement With Medirista For Recombinant Annexin A5 12
Acquisition 13
Ostersjostiftelsen Consortium to Acquire Stake in Athera Biotechnologies from Karolinska Development 13
Athera Biotechnologies AB – Key Competitors 15
Athera Biotechnologies AB – Key Employees 16
Athera Biotechnologies AB – Locations And Subsidiaries 17
Head Office 17
Appendix 18
Methodology 18
About GlobalData 18
Contact Us 18
Disclaimer 18

List of Tables
Athera Biotechnologies AB, Pharmaceuticals & Healthcare, Key Facts 2
Athera Biotechnologies AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Athera Biotechnologies AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Athera Biotechnologies AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Athera Biotechnologies AB, Deals By Therapy Area, 2012 to YTD 2018 8
Athera Biotechnologies AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Athera Biotech Raises USD7.2 Million in Venture Financing 10
Athera Biotechnologies Raises USD2.8 Million in Venture Financing 11
Athera Biotech Enters Into Agreement With Medirista For Recombinant Annexin A5 12
Ostersjostiftelsen Consortium to Acquire Stake in Athera Biotechnologies from Karolinska Development 13
Athera Biotechnologies AB, Key Competitors 15
Athera Biotechnologies AB, Key Employees 16

List of Figures
Athera Biotechnologies AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Athera Biotechnologies AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Athera Biotechnologies AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Athera Biotechnologies AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Athera Biotechnologies AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Athera Biotechnologies AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Athera Biotechnologies AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Athera Biotechnologies AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Athera Biotechnologies AB:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • The Middleby Corporation (MIDD):企業の財務・戦略的SWOT分析
    The Middleby Corporation (MIDD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Opsens Inc (OPS):医療機器:M&Aディール及び事業提携情報
    Summary Opsens Inc (Opsens), formerly DCB Capital Inc, is a provider of fiber optic sensing technology solutions. The company focuses on fractional flow reverse guidewire in interventional cardiology. It offers OptoWire, an optical-based pressure guidewire, which enhances the clinical outcome of pat …
  • Tech Mahindra Limited:企業の戦略・SWOT・財務分析
    Tech Mahindra Limited - Strategy, SWOT and Corporate Finance Report Summary Tech Mahindra Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Intra-Cellular Therapies Inc (ITCI):企業の財務・戦略的SWOT分析
    Summary Intra-Cellular Therapies Inc (ICTI) is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurodegenerative diseases. Its pipeline products include lumateperone (ITI-007), used for the treatment of schizophrenia, behavioral disturbances associat …
  • Freehold Royalties Ltd (FRU):企業の財務・戦略的SWOT分析
    Summary Freehold Royalties Ltd (Freehold Royalties), formerly Freehold Royalty Trust is an oil and gas company that offers oil and gas operation and financial performance. Its oil and gas assets generate income from natural gas, crude oil, natural gas liquids and potash deposits. It provides horizon …
  • FuelCell Energy Inc (FCEL):企業の財務・戦略的SWOT分析
    FuelCell Energy Inc (FCEL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • C&D Technologies Inc:企業の戦略的SWOT分析
    C&D Technologies Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Standard Alliance Insurance Plc:企業の戦略・SWOT・財務分析
    Standard Alliance Insurance Plc - Strategy, SWOT and Corporate Finance Report Summary Standard Alliance Insurance Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Coal India Ltd:戦略・SWOT・企業財務分析
    Coal India Ltd - Strategy, SWOT and Corporate Finance Report Summary Coal India Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Mannatech Inc (MTEX):企業の財務・戦略的SWOT分析
    Mannatech Inc (MTEX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Mangalam Drugs and Organics Ltd (MANGALAM):企業の財務・戦略的SWOT分析
    Summary Mangalam Drugs and Organics Ltd (MDOL) is a chemical manufacturing company that manufactures, develops, and supplies specialty chemicals, intermediates, and active pharmaceutical ingredients. The company's active pharmaceutical ingredients include amodiaquine HCl, bisoprolol fumarate, chloro …
  • equensWorldline SE:企業の戦略・SWOT・財務情報
    equensWorldline SE - Strategy, SWOT and Corporate Finance Report Summary equensWorldline SE - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Galapagos NV:企業のM&A・事業提携・投資動向
    Galapagos NV - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Galapagos NV Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • Chemetall GmbH:企業の戦略的SWOT分析
    Chemetall GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Da Afghanistan Breshna Sherkat:企業の戦略的SWOT分析
    Da Afghanistan Breshna Sherkat - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • Pioneer Natural Resources Co (PXD):企業の財務・戦略的SWOT分析
    Pioneer Natural Resources Co (PXD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Axxam SpA-製薬・医療分野:企業M&A・提携分析
    Summary Axxam SpA (Axxam) is a partner research organization that provides drug discovery services. The organization offers drug discovery services such as molecular biology, assay development and reagent provision, compound management, hit characterization and profiling and electrophysiology, among …
  • Hokkaido Electric Power Co Inc (9509):企業の財務・戦略的SWOT分析
    Hokkaido Electric Power Co Inc (9509) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • Endonovo Therapeutics Inc (ENDV):製薬・医療:M&Aディール及び事業提携情報
    Summary Endonovo Therapeutics Inc (Endonovo Therapeutics) is a commercial stage development company that offers non-invasive medical devices and equipment. The company’s products include Electroceutical Therapy a FDA-Cleared for the palliative treatment of pain and post-surgical edema and CE Marked …
  • TIS Inc (3626):企業の財務・戦略的SWOT分析
    TIS Inc (3626) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆